• Dr. Reddy's US generics business drags Q1 earnings, eyes weight-loss drug launch in 87 countries

    Source: Buzz FX / 23 Jul 2025 09:45:46   America/Los_Angeles


    Dr. Reddy’s Laboratories Ltd’s US generics business slumped in the June quarter as it faced price erosion in key products like gRevlimid used to treat cancer.
    US generics revenue declined 11% year-on-year and 4% sequentially to ₹3,412 crore
    Read more...
Share on,